Enliven Therapeutics (NASDAQ: ELVN) net income
Enliven Therapeutics reported a net loss of $103.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $89.0m. Earnings per share were −$1.83.
Enliven Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$103.7m | — | — | −$1.83 |
| 2024 | −$89.0m | — | — | −$1.89 |
| 2023 | −$71.6m | — | — | −$2.01 |
| 2022 | −$37.7m | — | — | −$12.05 |
| 2021 | −$51.4m | — | — | −$2.37 |
| 2020 | −$41.4m | — | — | — |
| 2019 | −$23.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Enliven Therapeutics net income compared with its sector
By net income for its latest fiscal year, Enliven Therapeutics ranks 338th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 336th | Perspective Therapeutics | −$103.1m | — |
| 337th | Schrodinger | −$103.3m | −40.4% |
| 338th | Enliven Therapeutics | −$103.7m | — |
| 339th | Nkarta | −$104.1m | — |
| 340th | C4 Therapeutics | −$105.0m | −292.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Enliven Therapeutics
- How much did Enliven Therapeutics earn in fiscal 2025?
- Enliven Therapeutics reported a net loss of $103.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $89.0m.
- What are the earnings per share of Enliven Therapeutics?
- They were −$1.83 in fiscal 2025, compared with −$1.89 in fiscal 2024.
- Where does Enliven Therapeutics rank in its sector by net income?
- It ranks 338th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Enliven Therapeutics come from?
- From the annual report (Form 10-K) that Enliven Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Enliven Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Enliven Therapeutics: the Enliven Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.